Jun 9, 2008 - Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its wholly owned subsidiary, Sucampo Pharma Europe, Ltd. (SPE), filed a Marketing Authorization Application (MAA) in Switzerland for AMITIZA (lubiprostone) for the indication of Chronic Idiopathic Constipation in adults. The MAA was filed with Swissmedic by Sucampo Pharmaceuticals' branch office in Basel, Switzerland.
The submission is part of the ongoing development of AMITIZA 24 mcg which was first launched in the United States in April 2006 for the treatment of Chronic Idiopathic Constipation in adults. In May 2008, AMITIZA 8 mcg was launched for the treatment of Irritable Bowel Syndrome with Constipation in adult women. Earlier this year, MAAs were filed in nine European countries for Chronic Idiopathic Constipation in adults at 24 mcg and are currently under review.
The details can be read here.
No comments:
Post a Comment